Allogene Therapeutics Inc. (NASDAQ:ALLO) does about 1.88M shares in volume on a normal day but saw 1558387 shares change hands in Monday trading. The company now has a market cap of 962.05M USD. Its current market price is $6.86, marking an increase of 4.73% compared to the previous close of $6.55. The 52 week high reached by this stock is $17.49 whilst the lowest price level in 52 weeks is $5.41. The script in recent trading has seen the stock touch a high of $7.085 and a low of $6.4147.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Allogene Therapeutics Inc. (ALLO) has a 20-day trading average at $6.25 and the current price is -60.78% off the 52-week high compared with 26.92% distance from its 52-week low. The 50-day simple moving average of the closing price is $7.91 and its 200-day simple moving average is $10.32. If we look at the stock’s price movements over the week, volatility stands at 7.72%, which increases to 7.77% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 49.90 to suggest the stock is neutral.
19 analysts observing the Allogene Therapeutics Inc. (ALLO) stock have set the 12-month price targets for the company’s shares at between $6.00 and $55.00. The consensus objective for the share price is $22.53, suggesting that the stock has a potential upside of 69.55% over the period. The median price target is 63.89% away from the current levels at $19.00.
FactSet Research has provided data showing that 19 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 1 advise that it is a overweight. 13 analysts have rated it as a buy and 4 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on January 06, 2023 when Robert W. Baird upgraded the stock to “Outperform” and issued a price target of $12. BofA Securities downgraded the stock to “Underperform” from Buy on December 12, 2022 at a price target of $24-$9.
The current price level is 10.34%, -13.68%, and -33.60% away from its SMA20, SMA50, and SMA200 respectively, with the ALLO price moving above the 50-day SMA on January 23. Allogene Therapeutics Inc. (ALLO) stock is down -2.83% over the week and 8.89% over the past month. Its price is 9.06% year-to-date and -40.76% over the past year.
The stock last released its quarterly earnings report for quarter ended 9/29/2022, with the company’s earnings per share (EPS) of -$0.58 above consensus estimates by $0.06. The company’s next earnings report is expected on 05/10/2023, with forecasts estimating quarterly EPS at -$0.7 and -$2.36 for whole year. ALLO’s earnings per share are forecast to shrink by -24.90% this year and -16.10% over next year. In addition, estimates put the company’s current quarterly revenue at an average of $60k.
Its 12-month price target is $19.00. To reach the target analysts have set, the stock logically needs to grow 69.55 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $6.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $55.00.
Outstanding shares total 143.66M with insiders holding 29.79% of the shares and institutional holders owning 76.09% of the company’s common stock. The company has a return on investment of -27.90% and return on equity of -37.70%. The beta has a value of 0.71. Price to book ratio is 1.33 and price to sales ratio is 4810.23.
According to a U.S. Securities and Exchange Commission filing, SPDR S&P Biotech ETF has added its position in Allogene Therapeutics Inc. (ALLO) to 7,424,210 shares, mirroring a recent increase by 0.41%. SPDR S&P Biotech ETF added 30016.0 shares of Allogene Therapeutics Inc. common stock bringing its total worth to about $46.7 million at the end of recent close, SEC documents show.
